An observational study in Glaucoma Patients and Healthy Controls, sponsored by University of Zurich. Status unknown at 1 site in Switzerland. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-01-06.
Sponsored by University of Zurich · Observational
To assess the improvement in reproducibility of 100 vs. 16 averaged images by Automatic Real Time (ART) using Spectralis™ Spectral Domain-Optical Coherence Tomography (SD-OCT, Heidelberg Engineering GmbH, Heidelberg, Germany) in retinal nerve fiber layer thickness (RNFL) circle scan-measurements.
University of Zurich is the lead sponsor of 1,048 studies on the registry; 132 are open to participants now.
Counted across the registry records on this site, refreshed daily.
patients and controls are selected out of our primary care clinic
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
for both groups (glaucoma study group and control group): men and women of at least 50 years of age
for the glaucoma study group: diagnosis of primary open angle glaucoma (POAG)
Exclusion criteria:
for both groups (glaucoma study group and control group):
for the glaucoma study group: other glaucoma diagnosis then primary open angle glaucoma
for the control group: any diagnosis of glaucoma
age matched healthy controls
Device: Spectralis® SD-OCT, Heidelberg Engineering GmbH, H
patients with diagnosis of primary open angle glaucoma
Device: Spectralis® SD-OCT, Heidelberg Engineering GmbH, H
Measurement of the peripapillar nerve fiber layer with different settings of ART
COV
Time frame: T0
This study is status unknown, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.